IMAX’s trailing P/E ratio stands at 28.4x, well below Live Nation’s 34.7x, suggesting a more attractive entry point for value investors. On an EV/EBITDA basis, IMAX trades at 16.5x versus Live Nation’s 21.2x. Despite Live Nation’s larger scale in live events, IMAX’s leaner cost structure and higher gross margin of 52% (compared to Live Nation’s 45%) underpin its relative undervaluation in the Film and Television Production and Distribution sector.

On January 10, IMAX was upgraded to a Zacks Rank #2 (Buy) following the company’s better-than-expected Q3 results, which featured revenue of $224 million (up 15% year-over-year) and adjusted EPS of $0.32, a 20% increase from the prior year. Zacks analysts cited upward revisions to full-year EPS forecasts—from $1.10 to $1.25—driven by stronger domestic box office performance and a 10% rise in international premium ticket sales across IMAX’s 1,700-screen global network.

IMAX’s pipeline includes 18 new screen installations in China during Q4 and a partnership with a major Hollywood studio to release at least six exclusives in IMAX format in 2024. Management projects capital expenditures of $40 million for network expansion, while maintaining free cash flow generation above $150 million annually. Investors should weigh these growth drivers against rising interest rates and the company’s near-term debt amortization schedule, which includes $120 million in maturities over the next 18 months.